A review based on a quick and heavily compromised cost-effectiveness evaluation conducted in secret with a threat to delist unless the company accepted a significant price reduction. Apparently, this is what constitutes a pricing negotiation in 2019. …
Latest Video
New Stories
-
PEFO confirms MA secured ATAGI fee delay
April 18, 2019 - - Latest News -
'Right to Trial' in blood cancers-a limited version of Trump's 'Right to Try'
April 18, 2019 - - Latest News -
MA starts communication on 'principles' Code
April 18, 2019 - - Latest News -
Pfizer goes red for World Haemophilia Day
April 18, 2019 - - Latest News -
Labor commits to 'early access' trials
April 17, 2019 - -
AusBiotech laments 'wearisome' uncertainty over fate of R&D tax incentive
April 17, 2019 - - Latest News -
Jacinda Ardern: 'Work to be done' on PHARMAC
April 17, 2019 - - Latest News